A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
Clinical trial NCT04008030 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04008030
- Sponsor
- Bristol-Myers Squibb
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-08-05
- Primary completion
- 2024-08-28
- Enrollment
- 839
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.